Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI
✍ Scribed by Roar Johansen; Line R. Jensen; Jana Rydland; Pål E. Goa; Kjell A. Kvistad; Tone F. Bathen; David E. Axelson; Steinar Lundgren; Ingrid S. Gribbestad
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 990 KB
- Volume
- 29
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Purpose
To evaluate dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) as a tool for early prediction of response to neoadjuvant chemotherapy (NAC) and 5‐year survival in patients with locally advanced breast cancer.
Materials and Methods
DCE‐MRI was performed in patients scheduled for NAC (n = 24) before and after the first treatment cycle. Clinical response was evaluated after completed NAC. Relative signal intensity (RSI) and area under the curve (AUC) were calculated from the DCE‐curves and compared to clinical treatment response. Kohonen and probabilistic neural network (KNN and PNN) analysis were used to predict 5‐year survival.
Results
RSI and AUC were reduced after only one cycle of NAC in patients with clinical treatment response (P = 0.02 and P = 0.08). The mean and 10th percentile RSI values before NAC were significantly lower in patients surviving more than 5 years compared to nonsurvivors (P = 0.05 and 0.02). This relationship was confirmed using KNN, which demonstrated that patients who remained alive clustered in separate regions from those that died. Calibration of contrast enhancement curves by PNN for patient survival at 5 years yielded sensitivity and specificity for training and testing ranging from 80%–92%.
Conclusion
DCE‐MRI in locally advanced breast cancer has the potential to predict 5‐year survival in a small patient cohort. In addition, changes in tumor vascularization after one cycle of NAC can be assessed. J. Magn. Reson. Imaging 2009;29:1300–1307. © 2009 Wiley‐Liss, Inc.